Leymus Genomics ApS: Financial statements 2019
CVR: 38106872
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
Leymus Genomics ApS (CVR 38106872) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK -156,060 and a net result of DKK -369,902 compared with DKK -228,302 the year before. Equity in the 2019 report amounted to DKK 290,957. The solvency ratio was 74.6%.
- Gross Profit
- DKK -156,060
- Profit/Loss
- DKK -369,902
- Equity
- DKK 290,957
- Total Assets
- DKK 389,890
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | -156K | -370K | 291K | - |
| 2018 | - | -186K | -228K | 161K | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
Leymus Genomics ApS has published its annual report for 2018. Gross profit came to DKK -185,782, and the net result was DKK -228,302.
About Leymus Genomics ApS
Leymus Genomics ApS was a Danish company of the type Anpartsselskab based in Herlev, founded in 2016. The company has been dissolved on 28 November 2024. The company was registered under the industry Engroshandel med andre maskiner og andet udstyr. The company was previously named Leymus Scientific Capital ApS. The company has 3 employees (2023). In 2023, the company reported a gross profit of DKK -1,341,461 and a net result of DKK -1,269,016 compared with DKK -1,655,772 the year before. Equity in the 2023 report amounted to DKK -124,553.